Clinical Trial Update: A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study evaluating the safety and efficacy of CP-690,550 (tofacitinib) in moderate to severe Crohn's disease, with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2012-12-31